ClinicalTrials.gov
ClinicalTrials.gov Menu

Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC (DUBLIN-3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02504489
Recruitment Status : Recruiting
First Posted : July 22, 2015
Last Update Posted : May 23, 2018
Sponsor:
Information provided by (Responsible Party):
BeyondSpring Pharmaceuticals Inc.

Brief Summary:

To compare the overall survival of NSCLC patients receiving 2nd- or 3rd-line systemic therapy with docetaxel + plinabulin (DP Arm) to patients treated with docetaxel + placebo (D5W) (D Arm) for advanced or metastatic disease.

Secondary purposes of the study are:

  • To compare the neutropenia (incidence of Grade 4 neutropenia [absolute neutrophil count (ANC) < 0.5 × 10^9/L]) on Day 8 (+/- 1 day) of Cycle 1), DoR, neutrophil count on Day 8 (+/- 1 day) of Cycle 1, incidence of docetaxel dose reduction and/or docetaxel dose withheld in Cycle 2 due to neutropenia in Cycle 1, QoL (EORTC QLQ-C30 [item 30, average overall quality of life over all observable weeks]), ORR, and PFS in patients with NSCLC treated in the DP Arm to patients treated in the D Arm as 2nd- or 3rd-line therapy for advanced or metastatic disease.
  • To compare the safety and adverse events profile of the DP Arm to D Arm.
  • To compare dose intensity of docetaxel (percent dose administered compared to dose assigned) between the 2 treatment arms.
  • To evaluate population pharmacokinetics in patients enrolled in the Western countries and China.

Condition or disease Intervention/treatment Phase
Non-Small Cell Lung Cancer Drug: Docetaxel + Plinabulin (DP) Drug: Docetaxel (D) Phase 3

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 554 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Blinded Phase III Assessment of Second or Third-Line Chemotherapy With Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced Non-Small Cell Lung Cancer and With at Least One Measurable Lung Lesion
Actual Study Start Date : July 2016
Estimated Primary Completion Date : November 2018
Estimated Study Completion Date : April 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Docetaxel

Arm Intervention/treatment
Active Comparator: Docetaxel (D)
A treatment cycle is 21 days. Treatment will be repeated until disease progression is detected by imaging studies or unacceptable toxicities are encountered. On Day 1, all patients will receive docetaxel 75 mg/m2 by intravenous (IV) infusion over 1 hour. Oral dexamethasone (16 mg, given as 8 mg twice daily) will be given on the day prior to, the day of (Day 1), and the day following docetaxel infusion (Day 2). Routine antiemetic prophylaxis will be administered according to institutional guideline for docetaxel. Institutional guideline/practice should be followed in the event of infusion/hypersensitivity reaction. Diphenhydramine and dexamethasone infusion may be administered in the event of infusion reaction.
Drug: Docetaxel (D)
Docetaxel 75 mg/m2 IV
Other Name: Taxotere

Experimental: Docetaxel + Plinabulin (DP)

The treatment regimen for Docetaxel (D) will be followed for this arm. In addition, on Days 1 and 8 of the 21 day cycle, patients will receive Plinabulin (P) administered via IV infusion over 60 minutes. On Day 1, the infusion begins 2 hours from the starting time of docetaxel infusion, i.e, approximately 60 minutes from the end of docetaxel infusion. On day 8, plinabulin infusion will be repeated.

On Day 1, no pre-medication will be routinely administered for plinabulin infusion. Anti-emetics may be prescribed as indicated according to institutional guidelines for chemotherapy. On Day 8, antiemetic prophylaxis may be administered prior to plinabulin infusion. For Cycle 1 Day 8 only, Zofran® (ondansetron) is prohibited due to its interference with QTc study.

Drug: Docetaxel + Plinabulin (DP)
Docetaxel 75 mg/m2 IV + Plinabulin 30 mg/m2
Other Name: BPI-2358, NPI-2358

Drug: Docetaxel (D)
Docetaxel 75 mg/m2 IV
Other Name: Taxotere




Primary Outcome Measures :
  1. Overall Survival [ Time Frame: Approximately 2 years after study initiation ]
    To compare the overall survival of NSCLC patients receiving 2nd- or 3rd-line systemic therapy with docetaxel + plinabulin (DP Arm) to patients treated with docetaxel + placebo (D5W) (D Arm) for advanced or metastatic disease.


Secondary Outcome Measures :
  1. To compare the Grade 4 neutropenia on Day 8 (+/- 1 day) of Cycle 1), DoR, neutrophil count on Day 8 (+/- 1 day) of Cycle 1, incidence of docetaxel dose reduction and/or docetaxel dose withheld in Cycle 2 due to neutropenia in Cycle 1, QoL ORR, and PFS [ Time Frame: Approximately 2 years after study initiation. ]
    Comparisons between DP and D + placebo arms will be based on incidence of Grade 4 neutropenia on Day 8 of Cycle 1 (all data and by subgroups of tumor status)

  2. To compare the safety and adverse events profile of the DP Arm to D Arm. [ Time Frame: Approximately 2 years after study initiation. ]
    compare the safety and adverse events profile of the DP Arm to D Arm.

  3. To compare dose intensity of docetaxel (percent dose administered compared to dose assigned) between the 2 treatment arms. [ Time Frame: Approximately 2 years after study initiation. ]
    Dose intensity is the % of docetaxel actually administered compared to the planned dose of docetaxel per cycle compared between the 2 treatment arms

  4. To evaluate population pharmacokinetics in patients enrolled in the Western countries and China. [ Time Frame: Approximately 2 years after study initiation. ]
    evaluate the effect of intrinsic and extrinsic factors on the PK of plinabulin and its active metabolite(s), if identified, in humans



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

INCLUSION CRITERIA:

  1. ECOG performance status ≤ 2.
  2. Histopathologically or cytologically confirmed NSCLC.
  3. Disease progression during or after treatment with one or two treatment regimen(s) Treatment regimens can be chemotherapy, targeted therapy, biological therapy, or immunotherapy for advanced (Stage IIIB) or metastatic disease (Stage IV). Modification of a regimen to manage toxicity with a different drug does not constitute a new regimen. Maintenance therapy following platinum-based chemotherapy is not considered as a separate regimen. Adjuvant or neoadjuvant chemotherapy and/or chemo-radiation for early stage disease do not count as prior systemic therapy. Prior radiation therapy is not exclusionary. Prior immunotherapy with a PD-1/PD-L1 inhibitor is not exclusionary. Prior treatment for advanced or metastatic disease must have included a platinum-based regimen. (Treatment of early stage disease [Stage IIIA or earlier] with a platinum-containing therapy does not count).
  4. At least 1 lesion ≥10 mm in longest diameter in lung parenchyma.
  5. patients with nonsquamous NSCLC must have been tested for EGFR exon 19 deletion and Exon 21 L858R substitution mutation. Only patients without EGFR sensitizing mutations are eligible, and they must have progressed on platinum-based chemotherapy. Patients with known ALK-rearrangements should be treated with an appropriate tyrosine kinase inhibitor (TKI) before entering the study. The TKI regimen would count as a line of treatment
  6. Patients with active brain metastasis or leptomeningeal involvement with brain metastases who are asymptomatic, and whose lesions by imaging are at least stable and without interim development of new lesions for at least 4 weeks may be enrolled.
  7. All AE's of prior systemic therapy, surgery, or radiotherapy, must have resolved to CTCAE v 4.03 Grade ≤2, except for neurological AE's that must have resolved to Grade ≤1.
  8. The following laboratory results ≤14 days prior to study drug admin:

    Hgb ≥9 g/dL independent of transfusion or growth factor support; absolute neutrophil count 1.5x10^9/L independent of growth factor support; platelet count ≥100x10^9/L independent of transfusion or growth factor support; Serum total bilirubin ≤ ULN, unless the patient has a diagnosis of Gilbert's disease then serum bilirubin 3.0 times ULN;

  9. AST & ALT ≤2.5 x ULN(≤1.5 x ULN if alkaline phosphatase is > 2.5 x ULN), and serum creatinine ≤1.5 x ULN.
  10. Life expectancy >12 weeks.
  11. Female patients of childbearing potential have a negative pregnancy test at baseline.
  12. Signed informed consent.

EXCLUSION CRITERIA: Patients with any of the following:

  1. Administration of chemo, biological, immunotherapy, radiotherapy or investigational agent (therapeutic or diagnostic) ≤3 weeks prior to receipt of study medication. Major surgery, other than diagnostic surgery, ≤4 weeks before first study drug admin.
  2. Significant cardiac history:

    History of myocardial infarction or ischemic heart disease ≤1 year before 1st study drug administration; uncontrolled arrhythmia; history of congenital QT prolongation; ECG findings consistent with acute ischemic heart disease; NYHA Class III-IV cardiac disease; & uncontrolled hypertension: BP consistently >150 mm Hg systolic & 100 mm Hg diastolic in spite of antihypertensive medication

  3. Patients who have received prior treatment with docetaxel.
  4. Prior transient ischemic attack or cerebrovascular accident with in the past year. Neurologic toxicities ≥Grade 2 within 3 weeks of randomization.
  5. History of hemorrhagic diarrhea, inflammatory bowel disease or active uncontrolled peptic ulcer disease. (Concomitant therapy with ranitidine or its equivalent and/or omeprazole or its equivalent is acceptable.) History of ileus or other significant gastrointestinal disorder known to predispose to ileus or chronic bowel hypomotility.
  6. Active uncontrolled bacterial, viral, or fungal infection requiring systemic therapy.
  7. Known infection with human immunodeficiency virus (HIV) or active hepatitis A, B, or C.
  8. Known prior hypersensitivity reaction to any product containing polysorbate 80, Polyoxyethylene 15 hydroxystearate/Macrogol 15 Hydroxystearate (Solutol HS 15).
  9. Female subject who is pregnant or lactating
  10. Second malignancy unless in remission for >5 years. (Non-melanoma skin cancer or carcinoma in situ of the cervix treated with curative intent is not exclusionary.)
  11. Medical conditions that would impose excessive patient risk. Examples: uncontrolled diabetes, infection requiring parenteral anti infective treatment, liver failure, altered mental status or psychiatric condition that would interfere with the understanding of the informed consent.
  12. Unwilling or unable to comply with protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02504489


Contacts
Contact: Ramon Mohanlal, M.D. 1 (646)305-6387 rmohanlal@beyondspringpharma.com
Contact: Gordon L Schooley, Ph.D. 1 (858) 353-0704 gschooley@beyondspringpharma.com

Locations
United States, California
Pacific Cancer Medical Center, Inc. Recruiting
Anaheim, California, United States, 92801
Contact: Elizabeth Brown       elizabethg@pacificcancer.com   
Principal Investigator: Veena Charu, MD         
NICR: Synergy Hematology Oncology Recruiting
Los Angeles, California, United States, 90048
Contact: Anton Akulov    323-725-0657    aakulov@nicresearch.com   
Principal Investigator: Levon Qasabian, MD         
Innovative Clinical Research Institute Recruiting
Whittier, California, United States
Contact: Kirsten Bettino       kbettino@airesearch.us   
Principal Investigator: Eddie Thara, MD         
United States, Colorado
Memorial Health Care System Recruiting
Colorado Springs, Colorado, United States
Contact: Caralyn Hutchens       caralyn.henderson@uchealth.org   
Principal Investigator: Robert Hoyer, MD         
United States, Georgia
Peachtree Hematoloy-Oncology Consultants, PC Recruiting
Atlanta, Georgia, United States
Contact: Ann Johnston       AJohnston@piedmontcancerinstitute.com   
Principal Investigator: Trevor Feinstein, MD         
United States, Illinois
Carle Cancer Center Recruiting
Urbana, Illinois, United States, 61801
Contact: Joshua Ward       joshua.ward@carle.com   
Principal Investigator: Krishna Vasireddy, DO         
United States, Kentucky
University of Louisville-Brown Cancer Center Recruiting
Louisville, Kentucky, United States, 40202
Contact: Goetz Kloecker, MD       goetz.kloecker@louisville.edu   
Contact: Karen Carter, RN       k.carter@louisville.edu   
United States, Mississippi
Hattiesburg Clinic Hematology/Oncology Recruiting
Hattiesburg, Mississippi, United States, 39401
Contact: Tammy McBeth    601-288-2495    tmcbeth@forrestgeneral.com   
Principal Investigator: John Hrom, MD         
United States, Ohio
University of Cincinnati Not yet recruiting
Cincinnati, Ohio, United States, 45267
Contact: Nagia A Karim, MD       karimnf@uc.edu   
Toledo Cancer Center Recruiting
Toledo, Ohio, United States, 43623
Contact: Rex B Mowat, MD    419-473-3561      
Contact: Jessica Ciesler, RN    419-473-3561      
United States, Tennessee
Cookeville Regional Medical Center Cancer Center Recruiting
Cookeville, Tennessee, United States, 61801
Contact: Linda Moore       lamoore@crmchealth.org   
Principal Investigator: Paul Jacquin, MD         
Australia, New South Wales
Blacktown Cancer Centre Recruiting
Blacktown, New South Wales, Australia, 2148
Contact: Adnan Nagrial, MD    61 2 9845 6859    Adnan.Nagrial@health.nsw.gov.au   
Principal Investigator: Adnan Nagrial, MD         
Border Medical Oncology Research Unit Recruiting
East Albury, New South Wales, Australia, 2640
Contact: Craig Underhill, MD       cunderhill@bordermedonc.com.au   
Principal Investigator: Craig Underhill, MD         
Gosford Hospital Recruiting
Gosford, New South Wales, Australia, 2250
Contact: Matthew Wong, MD       Matt.wong@health.nsw.gov.au   
Principal Investigator: Matthew Wong, MD         
Australia, Queensland
Adult Mater Hospital Recruiting
South Brisbane, Queensland, Australia, 4101
Contact: Vikram Jain, MD       Vikram.Jain@mater.org.au   
Principal Investigator: Vikram Jain         
Australia, Victoria
Barwon Health Recruiting
Geelong, Victoria, Australia, 3220
Contact: Madhu Singh       MSINGH@BarwonHealth.org.au   
Principal Investigator: Madhu Singh, MD         
Peninsula and South East Oncology Recruiting
Melbourne, Victoria, Australia, 3199
Contact: Vinod Ganju, MD       vg@paso.com.au   
Principal Investigator: Vinod Ganju, MD         
Epworth Hospital Recruiting
Richmond, Victoria, Australia, 3121
Contact: Ross Jennens, MD       jennens@bigpond.net.au   
Principal Investigator: Ross Jennens, MD         
Australia, Western Australia
Fiona Stanley Hospital Recruiting
Murdoch, Western Australia, Australia, 6150
Contact: Andrew Kiberu, MD       Andrew.Kiberu@health.wa.gov.au   
Principal Investigator: Andrew Kiberu, MD         
Perth Oncology/Mount Hospital Recruiting
Perth, Western Australia, Australia, 6000
Contact: Guy van Hazel, MD       guy@perthoncology.com.au   
Principal Investigator: Guy van Hazel, MD         
St John of God Hospital, Subiaco Recruiting
Subiaco, Western Australia, Australia, 6008
Contact: Tim Clay, MD       drclayoncologist@gmail.com   
Principal Investigator: Tim Clay, MD         
Sponsors and Collaborators
BeyondSpring Pharmaceuticals Inc.

Additional Information:
Responsible Party: BeyondSpring Pharmaceuticals Inc.
ClinicalTrials.gov Identifier: NCT02504489     History of Changes
Other Study ID Numbers: BPI-2358-103
First Posted: July 22, 2015    Key Record Dates
Last Update Posted: May 23, 2018
Last Verified: May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Docetaxel
Diketopiperazines
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Anti-Bacterial Agents
Anti-Infective Agents